var title_f13_39_13936="Radiograph of pt with dialysis related amyloidosis";
var content_f13_39_13936=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F85529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F85529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radiograph of patient with dialysis related amyloidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by Robert E Cronin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_39_13936=[""].join("\n");
var outline_f13_39_13936=null;
var title_f13_39_13937="Chagas heart disease Echo";
var content_f13_39_13937=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Chronic Chagas' heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 220px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transthoracic echocardiogram in a patient with chronic Chagas' heart disease. Apical long axis (left panel) and four-chamber (right panel) views show left ventricular dilation and a large apical thrombus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_39_13937=[""].join("\n");
var outline_f13_39_13937=null;
var title_f13_39_13938="Approach subepithelial lesion";
var content_f13_39_13938=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Stepwise evaluation of subepithelial gastrointestinal tumors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 721px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eckardt, AJ, Wassef, W. Diagnosis of subepithelial tumors in the GI tract. Endoscopy, EUS, and histology: bronze, silver, and gold. Gastroint Endosc 2005; 62:209. Copyright &copy; 2005 American Society of Gastrointestinal Endoscopy.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_39_13938=[""].join("\n");
var outline_f13_39_13938=null;
var title_f13_39_13939="Bladder cancer treatment; non-muscle invasive (superficial) cancer";
var content_f13_39_13939=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Bladder cancer treatment; non-muscle invasive (superficial) cancer (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/39/13939/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/39/13939/contributors\" id=\"au1352\">",
"       Michael A O'Donnell, MD, FACS",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/39/13939/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/39/13939/contributors\" id=\"se2767\">",
"       Seth P Lerner, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/39/13939/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/39/13939/contributors\" id=\"de8229\">",
"       Don S Dizon, MD, FACP",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?13/39/13939?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      BLADDER CANCER OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The optimal treatment for urothelial bladder cancer depends upon the cancer's stage and grade.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Approximately 70 percent of all new cases of bladder cancer are classified as non-muscle invasive, also called superficial bladder cancer. The initial treatment for this stage of bladder cancer is surgical removal of the tumor through a cystoscope (called TURBT). This is often followed by adjuvant (additional) therapy, which reduces the chances of the cancer recurring. (See",
"       <a class=\"local\" href=\"#H3\">",
"        'Transurethral resection of bladder tumor (TURBT)'",
"       </a>",
"       below.)",
"       <br/>",
"       <br/>",
"       Of these, approximately 20 to 25 percent of initially non-muscle invasive cancers will progress to invasive types during the person's lifetime.",
"      </li>",
"      <li>",
"       The remaining 30 percent of bladder cancers are muscle invasive, and generally require surgery to remove the bladder (cystectomy) and the surrounding organs. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15205?source=see_link\">",
"        \"Patient information: Bladder cancer treatment; invasive cancer (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     This article has facts about the treatment of non-muscle invasive urothelial bladder cancer. The diagnosis and staging of bladder cancer are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/12/31939?source=see_link\">",
"      \"Patient information: Bladder cancer diagnosis and staging (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      INITIAL BLADDER CANCER TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The most common first treatment of non-muscle invasive bladder cancer is surgery to remove any abnormal appearing areas inside the bladder; this is called transurethral resection of bladder tumor (TURBT).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Transurethral resection of bladder tumor (TURBT)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Transurethral resection of bladder tumor (TURBT) is a procedure in which a physician uses a cystoscope to see inside the bladder and remove any abnormal-appearing areas. A cystoscope is a long thin tube that contains a light and a camera.",
"    </p>",
"    <p>",
"     In most cases, this procedure is done in an operating room while the person is under anesthesia. After the procedure, you can usually go home, sometimes with a catheter for a few days.",
"    </p>",
"    <p>",
"     In certain cases, usually in people with more aggressive microinvasive cancers, a second TURBT will be performed several weeks after the first to be sure that no tumor was missed during the original cystoscopy. If there are new areas that appear abnormal, they will be removed. If there are no new abnormal-appearing areas, you will begin adjuvant therapy.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      ADJUVANT BLADDER CANCER THERAPY",
"     </span>",
"    </p>",
"    <p>",
"     Even in people who have their bladder tumor completely removed with TURBT, up to 50 percent of people will have a recurrence of their cancer within 12 months. Because of this high recurrence rate, adjuvant (additional) therapy is usually recommended. The type of adjuvant therapy recommended depends upon your risk of recurrence:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Some people who are at low risk of recurrence will be advised to have a single dose of intravesical chemotherapy at the time of the initial TURBT. (See",
"       <a class=\"local\" href=\"#H5\">",
"        'Intravesical chemotherapy'",
"       </a>",
"       below.)",
"       <br/>",
"       <br/>",
"       \"Intravesical\" means that the treatment is put inside of the bladder, usually through a catheter (a flexible tube passed through the urethra, where urine exits). This allows a high concentration of the treatment to be applied directly to the areas where tumor cells could remain, potentially destroying these cells and preventing them from reemerging in the bladder and forming new tumors.",
"      </li>",
"      <li>",
"       Some people who are at intermediate risk of recurrence will be advised to have either a full six-week course of intravesical chemotherapy, most commonly mitomycin, (see",
"       <a class=\"local\" href=\"#H5\">",
"        'Intravesical chemotherapy'",
"       </a>",
"       below) or intravesical immunotherapy with BCG (see",
"       <a class=\"local\" href=\"#H7\">",
"        'Intravesical BCG'",
"       </a>",
"       below).",
"      </li>",
"      <li>",
"       People at high risk of recurrence or worsening will be advised to start intravesical BCG, usually within two to six weeks of the first treatment. This is most commonly followed by additional booster treatments (maintenance therapy) once a complete response is obtained. Occasionally, however, patients are advised to consider bladder removal (cystectomy) especially if the disease is extensive.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The risk of recurrence is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/12/31939?source=see_link\">",
"      \"Patient information: Bladder cancer diagnosis and staging (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Intravesical chemotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemotherapy refers to the use of medicines to stop or slow the growth of cancer cells. The most commonly used intravesical chemotherapy for bladder cancer is mitomycin. This is put inside the bladder in one of two ways:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       One regimen involves giving the mitomycin once, immediately after TURBT. The solution is left in the bladder for 30 to 60 minutes, then allowed to drain out through a catheter.",
"      </li>",
"      <li>",
"       Alternately, the mitomycin can be given on a weekly basis for six weeks. With this regimen, the bladder is filled with mitomycin with a catheter, the solution is left for one to two hours, then the person urinates. A maintenance treatment may be given once per month for up to one year.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Mitomycin often causes temporary irritation of the bladder, including the need to urinate frequently and urgently and pain with urination. Mitomycin can also cause a skin rash on the palms of the hands, soles of the feet, and genitals. If this rash occurs, treatment with mitomycin is stopped and should not be restarted. A different chemotherapy drug or even BCG might be substituted in this situation. Rarely, mitomycin can cause the bladder to shrink down so that it holds less urine.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Intravesical BCG",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bacillus Calmette-Guerin (BCG) is a live bacterium related to cow tuberculosis. It is a common treatment for non-muscle invasive bladder cancer, particularly for cancers that have a risk of worsening over time. BCG is believed to work by triggering the body's immune system to destroy any cancer cells that remain in the bladder after TURBT.",
"    </p>",
"    <p>",
"     BCG is in a liquid solution that is put into the bladder with a catheter. The person then holds the solution in the bladder for two hours before they urinate. The treatment is usually given once per week for six weeks, starting approximately two to three weeks after the last TURBT. Further booster (maintenance) treatments can extend the benefit of BCG. (See",
"     <a class=\"local\" href=\"#H11\">",
"      'Maintenance BCG'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Benefits of intravesical BCG",
"     </span>",
"     &nbsp;&mdash;&nbsp;Intravesical BCG, in combination with TURBT, is the most effective treatment for non-muscle invasive bladder cancer. BCG therapy has been shown to delay (although not necessarily prevent) tumor growth to a more advanced stage, decrease the need for surgical removal of the bladder at a later time, and improve overall survival [",
"     <a class=\"abstract\" href=\"UTD.htm?13/39/13939/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Side effects of BCG",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people who are treated with intravesical BCG have some side effects; the most common of these include the need to urinate frequently, pain with urination, fever, blood in the urine, and body aches. These symptoms usually begin within two to four hours of treatment and resolve within 48 hours.",
"    </p>",
"    <p>",
"     Anyone who develops a fever (temperature greater than 100.4&ordm;F or 38&ordm;C) and drenching night sweats 48 hours or more after treatment with BCG should contact their healthcare provider. These may be signs of less common but more serious side effects, including bodywide infection.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      TESTING AFTER INITIAL BLADDER CANCER TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Tests are usually performed about three months after the start of intravesical treatment to be sure that the cancer has not recurred. If there are no signs of recurrence, maintenance BCG treatment may be recommended. (See",
"     <a class=\"local\" href=\"#H11\">",
"      'Maintenance BCG'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     If there are signs of cancer recurrence, any abnormal areas will be biopsied and removed with TURBT. Treatment after TURBT will depend upon the tumor's stage at recurrence and the amount of time that has passed since the first course of BCG was given. In general, there are two options: repeat a six-week course of weekly intravesical BCG or undergo surgical removal of the bladder (cystectomy). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15205?source=see_link\">",
"      \"Patient information: Bladder cancer treatment; invasive cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Maintenance BCG",
"     </span>",
"     &nbsp;&mdash;&nbsp;Maintenance intravesical BCG treatment is generally recommended for patients with high-risk non-muscle invasive bladder cancer. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/12/31939?source=see_link\">",
"      \"Patient information: Bladder cancer diagnosis and staging (Beyond the Basics)\"",
"     </a>",
"     .) The benefit of maintenance treatment is that it may further delay a recurrence of the cancer.",
"    </p>",
"    <p>",
"     Although the optimal duration of maintenance treatment is debated, several expert groups recommend that it be given for at least one year. Maintenance BCG is given once per week for three weeks at three, six, and 12 months after the initial BCG treatment. In some cases, maintenance BCG will be recommended for an extended period of time (at 18, 24, 30, and 36 months).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      SURVEILLANCE AFTER BLADDER CANCER TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Even in people who are treated appropriately, bladder cancer often recurs. Recurrent cancer can develop anywhere along the urinary tract, including the lining of the kidneys, ureters, urethra, and bladder. Close follow up after treatment is required to monitor for recurrence.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Cystoscopy and urine cytology",
"     </span>",
"     &nbsp;&mdash;&nbsp;Repeat cystoscopy and urine cytology testing are recommended for surveillance, beginning three months after treatment ends. If there are no signs of recurrence, cystoscopy and urine testing are usually recommended every three to six months for four years, and then once per year.",
"    </p>",
"    <p>",
"     If there are signs of recurrent bladder cancer, the next step depends upon several factors, including the person's age and underlying medical problems, the tumor's stage and grade at recurrence, previous treatments used, and the amount of time that has passed since the last course of treatment. In general, the options include a second course of intravesical BCG or surgical removal of the bladder (cystectomy). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15205?source=see_link\">",
"      \"Patient information: Bladder cancer treatment; invasive cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Imaging tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;The upper urinary tract (eg, kidneys, ureters) is lined with the same cells as the bladder. The tumors that develop in the bladder can develop in the upper urinary tract as well. As a result, an imaging test, such as a CT scan, is recommended after the initial course of treatment. This type of test is usually done every one to two years for all patients, except those with very low-risk disease.",
"    </p>",
"    <p>",
"     CT scanning and other types of imaging tests are described separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/12/31939?source=see_link\">",
"      \"Patient information: Bladder cancer diagnosis and staging (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413512586\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14515088\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/21/39250?source=see_link\">",
"      Patient information: Bladder cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14515103\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15205?source=see_link\">",
"      Patient information: Bladder cancer treatment; invasive cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/12/31939?source=see_link\">",
"      Patient information: Bladder cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29766?source=see_link\">",
"      Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35367?source=see_link\">",
"      Chemoprevention of bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=see_link\">",
"      Clinical presentation, diagnosis, and staging of bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=see_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29431?source=see_link\">",
"      Experimental systemic therapy of metastatic bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/39/5749?source=see_link\">",
"      Laparoscopic/robotic-assisted radical cystectomy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41992?source=see_link\">",
"      Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40409?source=see_link\">",
"      Nonurothelial bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27481?source=see_link\">",
"      Pathology of bladder neoplasms",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/39/634?source=see_link\">",
"      Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22039?source=see_link\">",
"      Screening for bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40122?source=see_link\">",
"      Treatment of non-muscle-invasive bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/34/32298?source=see_link\">",
"      Urinary diversion and reconstruction following cystectomy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov/cancertopics/types/bladder\">",
"      www.cancer.gov/cancertopics/types/bladder",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/bladdercancer.html\">",
"      www.nlm.nih.gov/medlineplus/bladdercancer.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Raghavan, D, Tuthill, K. Bladder Cancer &mdash; A Cleveland Clinic Guide for Patients, Cleveland Clinic",
"       <span class=\"nowrap\">",
"        Press/Kaplan",
"       </span>",
"       Press, Cleveland 2008.",
"      </li>",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org/",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Patient Support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Cancer Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://cancer.about.com/forum\">",
"      file://cancer.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?13/39/13939/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?13/39/13939?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13939/abstract/1\">",
"      Shelley MD, Court JB, Kynaston H, et al. Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer. Cochrane Database Syst Rev 2000; :CD001986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13939/abstract/2\">",
"      Smith JA Jr, Labasky RF, Cockett AT, et al. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 1999; 162:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13939/abstract/3\">",
"      Sylvester RJ, van der MEIJDEN AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168:1964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13939/abstract/4\">",
"      Mariappan P, Smith G, Lamb AD, et al. Pattern of recurrence changes in noninvasive bladder tumors observed during 2 decades. J Urol 2007; 177:867.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f13_39_13939=[""].join("\n");
var outline_f13_39_13939=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           BLADDER CANCER OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           INITIAL BLADDER CANCER TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           ADJUVANT BLADDER CANCER THERAPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           TESTING AFTER INITIAL BLADDER CANCER TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           SURVEILLANCE AFTER BLADDER CANCER TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f13_39_13940="Fluocinolone, hydroquinone, and tretinoin: Drug information";
var content_f13_39_13940=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluocinolone, hydroquinone, and tretinoin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/23/1397?source=see_link\">",
"    see \"Fluocinolone, hydroquinone, and tretinoin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F172279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tri-Luma&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F172296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Topical;",
"     </li>",
"     <li>",
"      Depigmenting Agent;",
"     </li>",
"     <li>",
"      Retinoic Acid Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F172281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Melasma: Topical: Apply a thin film once daily to affected areas; not indicated for use beyond 8 weeks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F172282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F172262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tri-Luma&reg;: Fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% (30 g) [contains sodium metabisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F172249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F172264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply 30 minutes before bedtime. Wash face with mild cleanser; rinse and pat dry. Apply to lesion and",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     inch of normal-appearing skin surrounding each lesion. Rub lightly and uniformly into the skin. Do not use occlusive dressings.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F172263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term treatment of moderate-to-severe melasma of the face",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F172294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Erythema (41%), desquamation (38%), burning (18%), dry skin (14%), pruritus (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Telangiectasia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Hyperesthesia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne (5%), pigmentation change (2%), irritation (2%), papules (1%), rash (1%), rosacea (1%), vesicles (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%: Other reactions reported with one or more components: Acneiform eruptions, allergic contact dermatitis, Cushing's syndrome, folliculitis, HPA axis suppression, hypopigmentation, itching, miliaria, ochronosis (exogenous), perioral dermatitis, secondary infection, skin atrophy, striae",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F172267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluocinolone, hydroquinone, tretinoin, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F172252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: Systemic absorption of topical corticosteroids may cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatitis: Cutaneous hypersensitivity/contact dermatitis to individual ingredients has been reported; instruct patients to seek medical attention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Exogenous ochronosis: Hydroquinone may produce exogenous ochronosis (gradual blue/black darkening of skin); discontinuation is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hormonal contraceptives: Consider changing to nonhormonal contraceptive measures in patients who may be receiving hormonal contraceptives.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children may absorb proportionally larger amounts of corticosteroids after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium metabisulfate: Contains sodium metabisulfite; may cause hypersensitivity reactions, including anaphylaxis, in individuals with sulfite allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Darker skin types: Has not been evaluated in skin types V and VI; excessive bleaching may occur in individuals with darker skin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient information: Instruct patients to avoid UV exposure, including sunlight (protective clothing and sunscreen recommended). Local irritation, dryness, and pruritus may be expected following application. Avoid contact with abraded skin, mucous membranes, eyes, nose, angles of the mouth.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F172290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F172256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F172275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Avoid excessive intake of vitamin A (cod liver oil, halibut fish oil).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid dong quai, St John's wort (may also cause photosensitization). Avoid excessive amounts of vitamin A supplements.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F172258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F172269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies in pregnant women. Tretinoin appears to have a low risk of teratogenicity when used topically since it is rapidly metabolized by the skin; however, there are rare reports of fetal defects. Risk may be greatest in 1st trimester. Use topically only if benefit to mother outweighs potential risk to fetus. In general, the use of topical corticosteroids during pregnancy is not considered to have significant risk, however, intrauterine growth retardation in the infant has been reported (rare). The use of large amounts or for prolonged periods of time should be avoided. Consider delaying treatment until after delivery.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F172285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F172270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid contact between nursing infant and cream.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F172268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Tri-Luma External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.01-4-0.05% (30 g): $120.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F172260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs/symptoms of HPA axis suppression",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Tri-Luma (AR, BR, CN, CO, HK, MX, MY, PE, PH, SG, TH, VE);",
"     </li>",
"     <li>",
"      Triluma (UY);",
"     </li>",
"     <li>",
"      Trimelasin (PK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F172251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not clearly defined. Hydroquinone may interrupt melanin synthesis (tyrosine-tyrosinase pathway); reduces hyperpigmentation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F172266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Minimal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic for the small amount absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/39/13940/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Torok HM, \"A Comprehensive Review of the Long-Term and Short-Term Treatment of Melasma With a Triple Combination Cream,\"",
"      <i>",
"       Am J Clin Dermatol",
"      </i>",
"      ,  2006, 7(4):223-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/39/13940/abstract-text/16901182/pubmed\" id=\"16901182\" target=\"_blank\">",
"        16901182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8781 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_39_13940=[""].join("\n");
var outline_f13_39_13940=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172279\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172296\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172281\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172282\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172262\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172249\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172264\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172263\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172294\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172267\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172252\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172290\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172256\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172275\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172258\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172269\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172285\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172270\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172268\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172260\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539861\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172251\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172266\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8781\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8781|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/23/1397?source=related_link\">",
"      Fluocinolone, hydroquinone, and tretinoin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_39_13941="Toremifene: Patient drug information";
var content_f13_39_13941=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Toremifene: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30181?source=see_link\">",
"     see \"Toremifene: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F229380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fareston&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F229381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fareston&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       An unsafe fast heartbeat may happen. Tell your doctor if you have a history of fast heartbeats, low potassium or magnesium levels. Your heartbeat will be watched with an ECG.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691763",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat breast cancer in women.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to toremifene or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Long QT syndrome, low magnesium levels, or low potassium levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697660",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There may be a higher chance of endometrial cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697133",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a fast heartbeat, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698594",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will watch your heartbeat with a test called an ECG.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do monthly breast self-exams and have a gynecologic exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698101",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698037",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Endometrial cancer may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698355",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stroke and blood clots may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3425219",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       An unsafe heartbeat may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698654",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12063 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-C2273CD5CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_39_13941=[""].join("\n");
var outline_f13_39_13941=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229380\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229381\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021620\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021622\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021621\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021626\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021627\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021629\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021624\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021625\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021630\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021631\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30181?source=related_link\">",
"      Toremifene: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_39_13942="Stapled uterine art ligation";
var content_f13_39_13942=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laparoscopic ligation of uterine arteries",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Placement of the stapling device for ligation of uterine arteries.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_39_13942=[""].join("\n");
var outline_f13_39_13942=null;
var title_f13_39_13943="Dorzolamide and timolol: Drug information";
var content_f13_39_13943=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dorzolamide and timolol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/53/5973?source=see_link\">",
"    see \"Dorzolamide and timolol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F161900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cosopt&reg;;",
"     </li>",
"     <li>",
"      Cosopt&reg; PF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F161901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Dorzo-Timop;",
"     </li>",
"     <li>",
"      Cosopt&reg;;",
"     </li>",
"     <li>",
"      Cosopt&reg; Preservative Free;",
"     </li>",
"     <li>",
"      Sandoz-Dorzolamide/Timolol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F161912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta-Blocker, Nonselective;",
"     </li>",
"     <li>",
"      Carbonic Anhydrase Inhibitor;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F161904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Reduction of intraocular pressure:",
"     </b>",
"     Ophthalmic: Instill 1 drop in affected eye(s) twice daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F530835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Reduction of intraocular pressure:",
"     </b>",
"     Ophthalmic: Children &ge;2 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F161905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15804888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clcr &lt; 30 mL/minute: Use is not recommended (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15804889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied): use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F161891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, ophthalmic [drops]: Dorzolamide 2% and timolol 0.5% (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cosopt&reg;: Dorzolamide 2% and timolol 0.5% (5 mL [DSC]; 10 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, ophthalmic [drops, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cosopt&reg; PF: Dorzolamide 2% and timolol 0.5% (0.2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F161882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes preservative free ophthalmic solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F595465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cosopt&reg;: If using additional topical ophthalmic preparations, separate administration by at least 10 minutes. Remove contact lens prior to administration and wait 15 minutes before reinserting. Instruct patients to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures. Ocular solutions can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may occur from using contaminated solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cosopt&reg; PF:  Discard single-use container after initial use.  If using additional topical ophthalmic preparations, separate administration by at least 5 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F161892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F161910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages as reported with combination product. Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     &gt;5%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Taste perversion (&le;30%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Burning/stinging (&le;30%), blurred vision (5% to 15%), conjunctival hyperemia (5% to 15%), itching (5% to 15%), superficial punctuate keratitis (5% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 5%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system:  Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, dyspepsia, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blepharitis, cloudy vision, conjunctival discharge, conjunctival edema, conjunctival follicles, conjunctivitis, corneal erosion, corneal staining, cortical lens opacity, dryness, eye debris, eye/eyelid discharge, eye/eyelid pain, eyelid edema, eyelid erythema, eyelid exudate/scales, foreign body sensation,  glaucomatous cupping, lens nucleus discoloration, lens opacity, post-subcapsular cataract,  tearing, visual field defect, vitreous detachment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough, pharyngitis, sinusitis, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Bradycardia, cardiac failure, cerebral vascular accident, chest pain, choroidal detachment (following filtration procedures), depression,  dyspnea, heart block, hypotension, iridocyclitis, MI, paresthesia,  photophobia, respiratory failure, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urolithiasis, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F161895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dorzolamide, timolol, or any component of the formulation; sinus bradycardia, heart block greater than first degree (except in patients with a functioning artificial pacemaker); cardiogenic shock; uncompensated cardiac failure; bronchospastic disease or asthma; history of bronchial asthma; severe COPD. Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F161885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Local ocular adverse effects (conjunctivitis and lid reactions) were reported with chronic administration; many resolved upon discontinuation of drug therapy. Choroidal detachment has been reported after filtration procedures. Patients with low endothelial cell counts may have increased risk for corneal edema; use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is not specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Systemic absorption and adverse effects (similar to sulfonamides) including blood dyscrasias, Stevens-Johnson syndrome, toxic epidermal necrolysis, and fulminant hepatic necrosis may occur with ophthalmic use. Bradycardia and/or hypotension may also occur due to beta-blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angle-closure glaucoma: Appropriate use: Should not be used alone in angle-closure glaucoma (has no effect on pupillary constriction).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with compensated heart failure and monitor for a worsening of the condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; not evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; may worsen disease or other myasthenic symptoms (diplopia, ptosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;  Peripheral vascular disease (PVD) and Raynaud's disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; not recommended with severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: In general, patients with mild-to-moderate COPD or bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Beta-blockers: Concomitant use with other topical beta-blockers should be avoided; monitor for increased effects (systemic or intraocular) with concomitant use of a systemic beta-blocker",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium channel blockers: Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral carbonic anhydrase inhibitors: Concurrent use with oral carbonic anhydrase inhibitors is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Some products may contain benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Absorption: Systemic absorption of timolol and adverse effects may occur with ophthalmic use, including bradycardia and/or hypotension. Beta-blocker therapy should not be withdrawn abruptly in order to avoid acute tachycardia, hypertension, and/or ischemia. Patients undergoing major surgery should be gradually tapered off therapy prior to procedure.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F161908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F161888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Management: Avoid concurrent use of different carbonic anhydrase inhibitors if possible.  Monitor patients closely for the occurrence of kidney stones and with regards to severity of metabolic acidosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; FluvoxaMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F518409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F518410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies in pregnant women with the combination product. Use only if benefit outweighs risk. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F518411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excreted in breast milk (timolol)/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F518412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Timolol is excreted in breast milk following oral and ophthalmic administration; however, it is unknown whether dorzolamide is also excreted. Therefore, use of the combination product during lactation cannot be recommended at this time.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F161897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cosopt Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     22.3-6.8 mg/mL (10 mL): $168.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cosopt PF Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     22.3-6.8 mg/mL (60): $96.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Dorzolamide HCl-Timolol Mal Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     22.3-6.8 mg/mL (10 mL): $122.49",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6825287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic exams and IOP periodically",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F161898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cosopt (AR, AU, BB, BE, BM, BR, BS, BZ, CH, CN, CO, DK, EC, ES, FI, FR, GY, HK, HN, IL, IT, JM, KP, MX, MY, NL, PE, PH, PK, SE, SG, SR, TH, TT, TW, UY, VE);",
"     </li>",
"     <li>",
"      Dorzoflax (PY);",
"     </li>",
"     <li>",
"      Dozola (TW);",
"     </li>",
"     <li>",
"      Oculpres-D (DO, HN);",
"     </li>",
"     <li>",
"      Timpilo (AU, BE, CH, CZ, DE, DK, FR, GR, HN, NL, RU, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6825285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dorzolamide: Inhibits carbonic anhydrase in the ciliary processes of the eye resulting decreased bicarbonate ion formation which decreases sodium and fluid transport, thus decreasing aqueous humor secretion and reduces intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Timolol: Blocks both beta",
"     <sub>",
"      1",
"     </sub>",
"     - and beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic receptors, reduces intraocular pressure by reducing aqueous humor production or possibly outflow",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F161894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/39/13943/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/39/13943/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/39/13943/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8903 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-4838B967EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_39_13943=[""].join("\n");
var outline_f13_39_13943=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161900\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161901\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161912\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161904\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F530835\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161905\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15804888\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15804889\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161891\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161882\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595465\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161892\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161910\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161895\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161885\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161908\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161888\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F518409\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F518410\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F518411\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F518412\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161897\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6825287\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161898\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6825285\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161894\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8903\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8903|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/53/5973?source=related_link\">",
"      Dorzolamide and timolol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_39_13944="Subungual melanoma - advanced";
var content_f13_39_13944=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75881%7EDERM%2F52821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75881%7EDERM%2F52821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subungual acral lentiginous melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Destruction of the nail bed by the tumor is present in this patient with subungual melanoma involving the toe. Note the presence of pigment involving the periungual skin (Hutchinson's sign).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subungual acral lentiginous melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Destruction of the nail bed by the tumor is present in this patient with subungual melanoma involving the toe. Note the presence of pigment involving the periungual skin (Hutchinson's sign).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_39_13944=[""].join("\n");
var outline_f13_39_13944=null;
var title_f13_39_13945="Pilar cyst 2";
var content_f13_39_13945=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66512%7EDERM%2F65892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66512%7EDERM%2F65892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pilar cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pilar cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_39_13945=[""].join("\n");
var outline_f13_39_13945=null;
var title_f13_39_13946="Treatment of osteomyelitis due to nontuberculous mycobacteria in adults";
var content_f13_39_13946=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of osteomyelitis due to nontuberculous mycobacteria in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/39/13946/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/39/13946/contributors\">",
"     Shannon Kasperbauer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/39/13946/contributors\">",
"     Charles L Daley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/39/13946/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/39/13946/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/39/13946/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/39/13946/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/39/13946/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H542359567\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontuberculous mycobacteria (NTM) are a vast group of organisms that are widespread in the environment (",
"    <a class=\"graphic graphic_table graphicRef61936 \" href=\"UTD.htm?3/0/3085\">",
"     table 1",
"    </a>",
"    ). They have been isolated from numerous environmental sources, including water and soil. NTM can cause a broad range of infections that vary depending on the NTM species and on the host&rsquo;s immune status. In immunocompetent individuals, disease can present as chronic pneumonia, lymphadenitis, or skin, soft tissue,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bone infection. Immunocompromised individuals can also present with any of these findings, but disease in such patients may also manifest as disseminated infection. Unfortunately, NTM are seldom considered as a possible etiology in infections of the soft tissues",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bones; therefore, delays in diagnosis and treatment are common.",
"   </p>",
"   <p>",
"    The treatment of osteomyelitis due to NTM will be reviewed here. The epidemiology, clinical manifestations, and diagnosis of NTM osteomyelitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/30/39401?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of osteomyelitis due to nontuberculous mycobacteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other NTM infections and the management of osteomyelitis due to bacteria and Mycobacterium tuberculosis are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24089?source=see_link\">",
"     \"Epidemiology of nontuberculous mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=see_link\">",
"     \"Microbiology of nontuberculous mycobacteria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15512?source=see_link\">",
"     \"Overview of nontuberculous mycobacteria (excluding MAC) in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38777?source=see_link\">",
"     \"Mycobacterium avium complex (MAC) infections in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2441?source=see_link\">",
"     \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5530?source=see_link\">",
"     \"Rapidly growing mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link\">",
"     \"Overview of osteomyelitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=see_link\">",
"     \"Hematogenous osteomyelitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22985?source=see_link\">",
"     \"Vertebral osteomyelitis and discitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10646?source=see_link\">",
"     \"Treatment and prevention of osteomyelitis following trauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24730?source=see_link\">",
"     \"Treatment of hematogenous osteomyelitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=see_link\">",
"     \"Skeletal tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1649190421\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomyelitis caused by nontuberculous mycobacteria (NTM) requires combination antimycobacterial therapy, often in conjunction with surgery. Concomitant immunosuppression should be minimized whenever possible. There are no randomized controlled trials or comparative observational studies that have evaluated the efficacy of treatment for NTM osteomyelitis. Thus, treatment recommendations are based upon case reports and small retrospective reviews, as well as on in vitro susceptibility patterns.",
"   </p>",
"   <p>",
"    Unlike isolation of M. tuberculosis, isolation of an NTM species does not necessarily dictate initiation of therapy. Because NTM can be isolated as a result of contamination of a clinical specimen and because the pathogenicity of the various NTM species varies substantially, clinicians must determine the clinical significance of any isolate and whether treatment is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, the results of in vitro susceptibility testing for many NTM do not correlate with clinical response, and therefore the clinician should use these data with an appreciation for the limitations of such testing.",
"   </p>",
"   <p>",
"    Our recommendations for therapy are generally in keeping with the 2007 American Thoracic",
"    <span class=\"nowrap\">",
"     Society/Infectious",
"    </span>",
"    Diseases Society of America",
"    <span class=\"nowrap\">",
"     (ATS/IDSA)",
"    </span>",
"    guidelines on the management of nontuberculous mycobacterial diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ]. These guidelines, as well as other ATS guidelines, can be accessed through the ATS website at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements/\">",
"     file://www.thoracic.org/statements/",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1979020487\">",
"    <span class=\"h1\">",
"     SUSCEPTIBILITY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro susceptibility testing is recommended for the majority of nontuberculous mycobacteria (NTM) species isolated from the lesions of patients with osteomyelitis, but specific recommendations differ for each species [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ]. For many NTM species, there is no known correlation between in vitro susceptibility results and the clinical response to therapy. In vitro susceptibility testing has not been validated for all NTM species. Despite these limitations, susceptibility testing plays an important role in the management of NTM osteomyelitis. Recommendations for susceptibility testing of each NTM species are discussed below. (See",
"    <a class=\"local\" href=\"#H758105564\">",
"     'Antimycobacterial therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Susceptibility testing for NTM species is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=see_link\">",
"     \"Microbiology of nontuberculous mycobacteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H758105564\">",
"    <span class=\"h1\">",
"     ANTIMYCOBACTERIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific antimycobacterial regimen depends upon the nontuberculous mycobacteria (NTM) species isolated and, for certain NTM species, on the results of in vitro susceptibility testing. It is important not to use monotherapy, since this can lead to the development of resistance.",
"   </p>",
"   <p>",
"    It is crucial to design a regimen based upon the specific NTM species, since there are differences in susceptibility among the species. The following generalizations can be made about the management of infections caused by rapidly and slowly growing mycobacteria, respectively:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rapidly growing mycobacteria are resistant to the antituberculosis agents, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      , but are susceptible to certain antibacterial agents. A macrolide, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      , is typically the cornerstone of the regimen for rapidly growing mycobacteria. Commonly used parenteral agents include an aminoglycoside, imipenem, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"       cefoxitin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Some of the slowly growing mycobacteria are susceptible to one or more of the antituberculosis agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      )",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      to antibacterial agents, such as macrolides",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aminoglycosides.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific regimens for each NTM species are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542359581\">",
"    <span class=\"h2\">",
"     Rapidly growing mycobacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with osteomyelitis caused by rapidly growing mycobacterial species should receive combination antimycobacterial therapy often in conjunction with surgery. (See",
"    <a class=\"local\" href=\"#H115152665\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Mycobacterium fortuitum, M. chelonae, and M. abscessus (including the subspecies, M. abscessus and M. bolletii [previously M. massiliense]) are resistant to antituberculosis agents, but they are typically susceptible to a number of traditional antibacterial agents [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro susceptibility testing should be performed on",
"    <strong>",
"     all",
"    </strong>",
"    clinically significant isolates of rapidly growing mycobacteria (eg, M. fortuitum complex, M. chelonae, M. abscessus), including isolates that have been recovered after treatment failure or relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ]. Antibacterial drugs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    , imipenem,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    , a sulfonamide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    , and clofazimine) should be tested, but the antituberculosis agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ) should not be tested since they do not possess activity. Moxifloxacin susceptibility testing is necessary even when ciprofloxacin is tested, since ciprofloxacin susceptibility cannot be extrapolated to moxifloxacin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5530?source=see_link&amp;anchor=H16#H16\">",
"     \"Rapidly growing mycobacterial infections in HIV-negative patients\", section on 'Susceptibility testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5530?source=see_link&amp;anchor=H18#H18\">",
"     \"Rapidly growing mycobacterial infections in HIV-negative patients\", section on 'Susceptibility patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542359588\">",
"    <span class=\"h3\">",
"     M. fortuitum complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. fortuitum complex includes M. fortuitum, M. peregrinum, and M. porcinum (previously classified as the third biovariant complex). Treatment involves combination antimycobacterial therapy with at least two agents with in vitro activity against the clinical isolate [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast to M. abscessus and M. chelonae, M. fortuitum is susceptible in vitro to multiple different antimicrobial agents. It is important to note that monotherapy is not considered appropriate, given the risk of inducing resistance. Agents that typically have in vitro activity against M. fortuitum complex include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    , sulfonamides, imipenem,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , and clofazimine [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. However, M. fortuitum carries an inducible",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    methylase gene erm (39), which confers macrolide resistance, and therefore macrolides should be avoided or used with caution (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5530?source=see_link&amp;anchor=H16#H16\">",
"     \"Rapidly growing mycobacterial infections in HIV-negative patients\", section on 'Susceptibility testing'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/6\">",
"     6",
"    </a>",
"    ]. Imipenem is the preferred carbapenem (rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"     ertapenem",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/42/6822?source=see_link\">",
"     doripenem",
"    </a>",
"    ). Some isolates are susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    For initial therapy, we suggest a combination of an oral agent and a parenteral agent to which the isolate is susceptible, adjusted for renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       An oral agent",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      (3.5 to 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      component every eight to twelve hours)",
"      <strong>",
"       or",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      400 mg once daily",
"      <strong>",
"       or",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      500 mg twice daily",
"      <strong>",
"       or",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      100 mg twice daily",
"      <br/>",
"      <br/>",
"      <strong>",
"       PLUS",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       An IV agent",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       Amikacin",
"      </a>",
"      15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV once daily or 25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV thrice weekly",
"      <strong>",
"       or",
"      </strong>",
"      imipenem 500 mg IV every six hours or 750 mg IV every eight hours",
"      <strong>",
"       or",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"       cefoxitin",
"      </a>",
"      3 g IV every six or eight hours &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest continuing this regimen for four to six weeks, and then switching to an oral regimen that includes two or three agents to which the isolate is susceptible in vitro. Therapy should be continued for at least six months total. (See",
"    <a class=\"local\" href=\"#H14965826\">",
"     'Duration of therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although no randomized trials or comparative observational studies have been performed, in one study that included 76 patients with nonpulmonary infections due to M. fortuitum, 68 patients (90 percent) were successfully treated with antimycobacterial therapy with or without surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/7\">",
"     7",
"    </a>",
"    ]. Most patients had skin and soft tissue infections, but 15 had osteomyelitis. The majority of patients with extensive disease underwent surgical debridement in combination with antimycobacterial therapy. Patients received a variety of regimens, ranging from combination parenteral therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    to oral monotherapy with a sulfonamide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , or amikacin. The mean duration of antimycobacterial therapy for patients with osteomyelitis was seven months. The treatment of M. fortuitum infections is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5530?source=see_link&amp;anchor=H17#H17\">",
"     \"Rapidly growing mycobacterial infections in HIV-negative patients\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542359595\">",
"    <span class=\"h3\">",
"     M. chelonae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of M. chelonae disease is difficult due to multidrug resistance and the dearth of oral antibiotics for therapy. Most microbiology laboratories are unable to differentiate between M. chelonae and M. abscessus. However, speciation is important because the in vitro susceptibility patterns differ between these species. In addition, due to the variable in vitro drug susceptibilities to some drugs, we recommend in vitro susceptibility testing of",
"    <strong>",
"     all",
"    </strong>",
"    clinically significant isolates.",
"   </p>",
"   <p>",
"    M. chelonae is more drug-resistant than M. fortuitum. The macrolides and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    are the only agents that can be given orally to which M. chelonae is typically susceptible [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1,4,8,9\">",
"     1,4,8,9",
"    </a>",
"    ]. Up to 20 percent of M. chelonae isolates from one case series were susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    , and sulfamethoxazole [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/8\">",
"     8",
"    </a>",
"    ]. Based on in vitro susceptibility patterns, the most promising parenteral agents are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/3\">",
"     3",
"    </a>",
"    ] and imipenem [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/5\">",
"     5",
"    </a>",
"    ]. Tobramycin has greater activity against M. chelonae than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/3\">",
"     3",
"    </a>",
"    ]; in contrast, the other rapidly growing mycobacteria are more susceptible to amikacin.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     Cefoxitin",
"    </a>",
"    does",
"    <strong>",
"     not",
"    </strong>",
"    have activity against M. chelonae [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For initial therapy, we suggest a combination of an oral macrolide and a parenteral agent to which the isolate is susceptible [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ]. The following dosing is for patients with normal renal function:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      500 mg orally once or twice daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      250 to 500 mg once daily",
"      <br/>",
"      <br/>",
"      <strong>",
"       PLUS",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"       Tobramycin",
"      </a>",
"      4 to 7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV once daily",
"      <strong>",
"       or",
"      </strong>",
"      imipenem 500 mg IV every six to eight hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration of parenteral therapy is not well defined. Factors that will influence the duration include extent of disease, host immunosuppression, susceptibility of the organism, and whether surgical debridement is performed. We usually continue the parenteral combination regimen for 8 to 12 weeks until there are signs of clinical improvement and we then switch to an oral regimen that includes two to three agents to which the isolate is susceptible (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ). Although linezolid has excellent in vitro activity, it is problematic since thrombocytopenia frequently occurs when it is used for a prolonged period. When linezolid is used for mycobacterial infections, the drug is usually administered at a dose of 600 mg once daily. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28298?source=see_link&amp;anchor=H2#H2\">",
"     \"Pharmacology of antimicrobial agents for treatment of methicillin-resistant Staphylococcus aureus and vancomycin resistant enterococcus\", section on 'Linezolid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapy should be continued for at least six months total. (See",
"    <a class=\"local\" href=\"#H14965826\">",
"     'Duration of therapy'",
"    </a>",
"    below.)",
"    <br/>",
"    <br/>",
"    In an observational study that included 47 patients with nonpulmonary infections due to M. chelonae or M. abscessus, 34 patients (72 percent) were successfully treated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/7\">",
"     7",
"    </a>",
"    ]. The outcomes for these two species were combined. Only seven patients had osteomyelitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542359602\">",
"    <span class=\"h3\">",
"     M. abscessus",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. abscessus (and its subspecies, M. abscessus and M. bolletii [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]), are challenging to treat because they are resistant to many agents that are used for other NTM infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ]. Given its drug-resistant nature, we suggest a combined medical and surgical approach for treatment of M. abscessus osteomyelitis. In addition, due to the variable in vitro drug susceptibilities to some drugs, we recommend in vitro susceptibility testing of",
"    <strong>",
"     all",
"    </strong>",
"    clinically significant isolates. The macrolides and clofazimine are the only oral agents with reliable in vitro activity against M. abscessus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1,3,5\">",
"     1,3,5",
"    </a>",
"    ]. Parenteral agents that typically have in vitro activity against M. abscessus include amikacin, cefoxitin, imipenem, and tigecycline.",
"   </p>",
"   <p>",
"    For initial therapy of M. abscessus, we suggest a combination of an oral macrolide and a parenteral agent to which the isolate is susceptible, adjusted for renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      500 mg orally twice daily",
"      <strong>",
"       or",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      250 to 500 mg orally once daily",
"      <br/>",
"      <br/>",
"      <strong>",
"       PLUS",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       Amikacin",
"      </a>",
"      15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV once daily or 25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV three times weekly",
"      <strong>",
"       or",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"       cefoxitin",
"      </a>",
"      3 g IV every six to eight hours",
"      <strong>",
"       or",
"      </strong>",
"      imipenem 500 mg IV every six to eight hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     Tigecycline",
"    </a>",
"    may be used in place of one of the agents suggested above in patients who are intolerant of or whose isolate displays in vitro drug resistance to the other drugs. The usual dosing is 100 mg IV as a loading dose, followed by 50 mg IV every 12 hours. However, patients with significant nausea and vomiting with the dose may need to be reduced to 50 mg IV once daily.",
"   </p>",
"   <p>",
"    We suggest continuing one of the regimens outlined above for at least 12 weeks, and then switching to an oral regimen. Appropriate oral regimens for patients with normal renal function include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      500 mg once or twice daily",
"      <strong>",
"       or",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      250 to 500 mg once daily",
"      <br/>",
"      <br/>",
"      <strong>",
"       PLUS",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      500 to 750 mg twice daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      400 mg once daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      600 mg once or twice daily or clofazimine 100 mg daily.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinicians should be aware that M. abscessus contains an erm (41) gene that confers inducible macrolide resistance; despite in vitro drug susceptibility, the macrolide may not be active in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/13\">",
"     13",
"    </a>",
"    ]. This should be considered in patients who are not responding to macrolide-based therapy. One study of M. abscessus isolates noted that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    induces greater erm (41) expression and thus higher macrolide resistance than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/14\">",
"     14",
"    </a>",
"    ]. Therefore, azithromycin may be more effective in M. abscessus infections. M. bolletii does not have a functional erm gene, so either macrolide can be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5530?source=see_link&amp;anchor=H16#H16\">",
"     \"Rapidly growing mycobacterial infections in HIV-negative patients\", section on 'Susceptibility testing'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    <br/>",
"    Treatment should be continued for a minimum of six months total. (See",
"    <a class=\"local\" href=\"#H14965826\">",
"     'Duration of therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The evidence for efficacy of regimens for M. abscessus comes primarily from retrospective studies of M. abscessus pulmonary infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5530?source=see_link&amp;anchor=H372828830#H372828830\">",
"     \"Rapidly growing mycobacterial infections in HIV-negative patients\", section on 'Efficacy'",
"    </a>",
"    ). One study of nonpulmonary infections caused by rapidly growing mycobacteria included 47 cases of M. chelonae, 32 of which were further classified as being M. chelonae spp abscessus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/7\">",
"     7",
"    </a>",
"    ]. The overall success rate for infections caused by M. abscessus or M. chelonae was 72 percent, but the major cause of treatment failure was the absence of an oral drug with activity against M. abscessus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542359609\">",
"    <span class=\"h3\">",
"     M. smegmatis",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. smegmatis isolates are typically susceptible in vitro to sulfamethoxazole,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , imipenem,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. They are usually resistant to the macrolides and are variably susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1,17\">",
"     1,17",
"    </a>",
"    ]. M. smegmatis is resistant to the antituberculosis agents, with the exception of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that patients receive the following regimen, adjusted for renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      100 mg orally twice daily",
"      <strong>",
"       or",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (3.5 to 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      component orally every eight to twelve hours)",
"      <br/>",
"      <br/>",
"      <strong>",
"       PLUS",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       Amikacin",
"      </a>",
"      15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV once daily",
"      <strong>",
"       or",
"      </strong>",
"      imipenem 500 mg IV every six to eight hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend continuing the parenteral regimen for a minimum of six to eight weeks with concomitant clinical improvement before switching to an oral combination regimen of at least two active agents. We recommend a total of six months of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542359616\">",
"    <span class=\"h2\">",
"     Slowly growing mycobacteria",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542359623\">",
"    <span class=\"h3\">",
"     M. avium complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with localized osteomyelitis due to M. avium complex, we suggest a combination of excisional surgery or surgical debridement and antimycobacterial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H115152665\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For M. avium complex (MAC) isolates, susceptibility testing should be performed for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    only. Since clarithromycin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    share cross-resistance and susceptibility, the results of clarithromycin susceptibility testing can be extrapolated to azithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ]. Clarithromycin susceptibility testing should be performed for new (previously untreated) isolates and for isolates from patients who have not responded to macrolide therapy after several months. In patients who fail initial macrolide-based therapy, we also suggest testing susceptibility to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    and clofazimine.",
"   </p>",
"   <p>",
"    We suggest that patients receive the following regimen, adjusted for renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      500 mg orally twice daily",
"      <strong>",
"       or",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      250 to 500 mg orally daily",
"      <br/>",
"      <br/>",
"      <strong>",
"       PLUS",
"      </strong>",
"      &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       Ethambutol",
"      </a>",
"      15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally daily",
"      <br/>",
"      <br/>",
"      <strong>",
"       PLUS",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once daily (maximum daily dose 600 mg); in HIV-infected patients receiving antiretroviral therapy with an agent that has stronger interactions with rifampin than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      , rifabutin 150 to 300 mg once daily can be used (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment of pulmonary tuberculosis in the HIV-infected patient\", section on 'Drug interactions'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    or intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    (each dosed at 8 to 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    two or three times per week) should be added for severe or disseminated infection or in patients who respond poorly to the regimen outlined above. We suggest that treatment generally be continued for 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ]. When amikacin or streptomycin is used, it is typically continued only for the first two or three months. (See",
"    <a class=\"local\" href=\"#H14965826\">",
"     'Duration of therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Immunocompromised patients generally require a more complex regimen to treat disseminated disease. Immunocompromised patients also require a longer duration of therapy. These issues are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38777?source=see_link\">",
"     \"Mycobacterium avium complex (MAC) infections in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=see_link&amp;anchor=H5#H5\">",
"     \"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542359630\">",
"    <span class=\"h3\">",
"     M. kansasii",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases of M. kansasii osteomyelitis, antimycobacterial therapy with a combined regimen similar to a regimen used for tuberculosis (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    ) has been successful even without surgical debridement [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/19-22\">",
"     19-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the initial treatment of M. kansasii, susceptibility testing should be performed for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    only. Isolates that demonstrate in vitro susceptibility to rifampin are also susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    . If the isolate is rifampin-resistant, susceptibility to other agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    , rifabutin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    , sulfonamides, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ) should be performed. Moxifloxacin susceptibility testing is necessary even when ciprofloxacin is tested, since ciprofloxacin susceptibility cannot be extrapolated to moxifloxacin.",
"   </p>",
"   <p>",
"    Rifamycins play a critically important role in the treatment of M. kansasii disease; therefore, it is important to use a rifamycin-based regimen even in the setting of concomitant antiretroviral therapy for HIV infection despite the drug-drug interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ]. This recommendation is based upon the observation that substantial rates of relapse occurred in the pre-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    era and that outcomes improved dramatically after the introduction of rifampin for the treatment of pulmonary M. kansasii infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1,23-26\">",
"     1,23-26",
"    </a>",
"    ]. The use of rifamycins in patients receiving antiretroviral therapy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\", section on 'Drug interactions'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    We suggest the following oral combination regimen for patients with M. kansasii osteomyelitis, adjusted for renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       Isoniazid",
"      </a>",
"      5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once daily (maximum daily dose 300 mg)",
"      <br/>",
"      <br/>",
"      <strong>",
"       PLUS",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once daily (maximum daily dose 600 mg)",
"      <br/>",
"      <br/>",
"      <strong>",
"       PLUS",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       Ethambutol",
"      </a>",
"      15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day",
"      <br/>",
"      <br/>",
"      <strong>",
"       PLUS",
"      </strong>",
"     </li>",
"     <li>",
"      Pyridoxine 25 to 50 mg once daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend continuing antimycobacterial therapy for at least six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542359637\">",
"    <span class=\"h3\">",
"     M. haemophilum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on reported cases, combinations of antibiotics including a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , and a rifamycin appear to be effective in the treatment of osteomyelitis caused by M. haemophilum [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1,27,28\">",
"     1,27,28",
"    </a>",
"    ]. In addition to these agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    also appears to have in vitro activity against M. haemophilum [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1,28,29\">",
"     1,28,29",
"    </a>",
"    ]. In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and sulfonamides have variable activity against M. haemophilum, and all clinical isolates are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/30\">",
"     30",
"    </a>",
"    ]. There are no standardized in vitro susceptibility methods for M. haemophilum; therefore, when in vitro susceptibility is performed, the results must be interpreted with caution [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the treatment of M. haemophilum, we suggest the following oral combination regimen, adjusted for renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      500 mg once or twice daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      250 to 500 mg once daily",
"      <br/>",
"      <br/>",
"      <strong>",
"       PLUS",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      500 mg twice daily",
"      <br/>",
"      <br/>",
"      <strong>",
"       PLUS",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once daily (maximum daily dose 600 mg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with extensive or severe disease, we add",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV once daily to the oral regimen described above. We continue the amikacin for 12 weeks, but we continue the three oral agents for a longer period. Therapy should continue for at least 6 months and for up to 24 months depending on the clinical response [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgery is performed in selected cases. (See",
"    <a class=\"local\" href=\"#H115152665\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542359644\">",
"    <span class=\"h3\">",
"     M. marinum",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. marinum isolates are usually susceptible in vitro to macrolides, rifamycins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    , and sulfonamides; susceptible or intermediately susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    ; and resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1,31\">",
"     1,31",
"    </a>",
"    ]. Susceptibility testing is not routinely recommended for M. marinum, but it should be performed in patients who do not respond to therapy after three months [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ]. When testing is performed, we suggest testing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    , ethambutol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , a sulfonamide, doxycycline, minocycline, and streptomycin.",
"   </p>",
"   <p>",
"    For the treatment of osteomyelitis due to M. marinum, we suggest the following oral regimen, adjusted for renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      500 mg once or twice daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      250 or 500 mg once daily",
"      <br/>",
"      <br/>",
"      <strong>",
"       PLUS",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       Ethambutol",
"      </a>",
"      15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day",
"      <br/>",
"      <br/>",
"      <strong>",
"       PLUS",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once daily (maximum daily dose 600 mg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend continuing antimycobacterial therapy for at least six months.",
"   </p>",
"   <p>",
"    Surgery is performed in selected cases. (See",
"    <a class=\"local\" href=\"#H115152665\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    M. marinum soft tissue infections are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31687?source=see_link&amp;anchor=H18#H18\">",
"     \"Soft tissue infections following water exposure\", section on 'Mycobacterium marinum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542359651\">",
"    <span class=\"h3\">",
"     M. ulcerans",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard of care for Buruli ulcer, which is caused by M. ulcerans, has been antimycobacterial therapy in combination with surgical debridement and skin grafting, when necessary. Susceptibility testing of M. ulcerans is difficult since this fastidious species does not grow in standard media without supplementation and extended incubation. Standardized guidelines for in vitro susceptibility testing of M. ulcerans have therefore not been developed. We do not recommend in vitro susceptibility testing of M. ulcerans isolates.",
"   </p>",
"   <p>",
"    The World Health Organization recommends a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally once daily) and either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intramuscularly once daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV once daily for eight weeks as first-line treatment for active disease, based on a small observational study [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Dosing should be adjusted for renal dysfunction.",
"   </p>",
"   <p>",
"    The treatment of Buruli ulcer is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39033?source=see_link\">",
"     \"Buruli ulcer (Mycobacterium ulcerans infection)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51756785\">",
"    <span class=\"h3\">",
"     Other species",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other slowly growing mycobacterial species that have been reported rarely to cause osteomyelitis include M. scrofulaceum, M. simiae, M. szulgai, M. terrae complex, and M. xenopi. The general approach to therapy is similar to the approach to the other slowly growing mycobacterial species. We suggest consultation with an infectious diseases specialist with experience treating infections with these organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14965826\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of antimycobacterial therapy depends upon several factors, including the extent of disease, response to treatment, the causative species, and the immune status of the patient. For most NTM species, antimycobacterial therapy should be continued for a minimum of six months and is sometimes given for 12 months or longer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14974796\">",
"    <span class=\"h2\">",
"     Monitoring during therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring for adverse effects of antimycobacterial therapy is important given the potential toxicities of the agents used. &nbsp;Patients should be monitored for evidence of hepatotoxicity (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    , rifamycins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ); nephrotoxicity (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    ); auditory and vestibular function (tobramycin, amikacin, streptomycin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ); and hematologic toxicity (rifamycins, sulfonamides,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    ). We check a complete blood count and a comprehensive metabolic panel (including liver function tests) monthly.",
"   </p>",
"   <p>",
"    For the aminoglycosides, this monitoring should include routine questioning about balance, ability to walk (especially in the dark), tinnitus, ear fullness, dizziness, and difficulty hearing. Baseline blood urea nitrogen and creatinine measurements should be obtained. Periodic monitoring of renal function is recommended for high-risk patients receiving an aminoglycoside, especially in patients older than 50 years or who have impairment of renal function. A baseline hearing test should be performed, especially in high-risk patients, and then repeated monthly, or sooner if signs or symptoms of eighth nerve toxicity appear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5530?source=see_link&amp;anchor=H26#H26\">",
"     \"Rapidly growing mycobacterial infections in HIV-negative patients\", section on 'Monitoring for drug toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Repeat imaging should be performed with any relapse in symptoms or lapse from treatment. Repeat imaging at the end of therapy is helpful to establish a new baseline. In addition, we typically repeat imaging six months after the completion of therapy to evaluate for possible relapse.",
"   </p>",
"   <p>",
"    We monitor serum inflammatory markers (erythrocyte sedimentation rate, C-reactive protein) when the diagnosis of osteomyelitis is first established and monthly during therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14973260\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antimycobacterial agents that are used to treat NTM osteomyelitis are often difficult to tolerate and some have important toxicities. Important adverse effects include (but are not limited to) ototoxicity and nephrotoxicity with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    , optic neuropathy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    , and hepatotoxicity with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    . The adverse effects of the agents used to treat NTM infections are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/34/24104?source=see_link\">",
"     \"Aminoglycosides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=see_link\">",
"     \"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=see_link\">",
"     \"Manifestations of and risk factors for aminoglycoside nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30757?source=see_link\">",
"     \"Ethambutol: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link\">",
"     \"Azithromycin, clarithromycin, and telithromycin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=see_link\">",
"     \"Rifampin and other rifamycins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19142?source=see_link\">",
"     \"Isoniazid: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41943?source=see_link\">",
"     \"Isoniazid hepatotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14973535\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunocompromised patients, such as solid organ transplant recipients, are often receiving immunosuppressive agents such as calcineurin inhibitors that interact with certain antimycobacterial agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ). These interactions are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=see_link&amp;anchor=H5#H5\">",
"     \"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain antiretroviral agents for HIV infection also have important interaction with the rifamycins, especially",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific interactions between medications may be determined using the drug interaction tool (Lexi-Interact Online). This tool can be accessed from the UpToDate online search page or through the individual drug information topics, section on Drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115152665\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery plays an important role in the treatment of nontuberculous mycobacteria (NTM) osteomyelitis, particularly since the rate of side effects and drug interactions from antimycobacterial therapy is high and may limit the tolerance to medical therapy alone. In addition, some NTM respond poorly to antimycobacterial therapy. No studies have been performed that have demonstrated the efficacy of surgical debridement for NTM osteomyelitis and no guidelines exist regarding which patients should undergo surgery in addition to medical therapy. Therefore, it is important that patients with osteomyelitis caused by NTM be seen by physicians with experience managing these difficult-to-treat infections.",
"   </p>",
"   <p>",
"    For patients with localized osteomyelitis due to M. avium complex, we suggest a combination of excisional surgery or surgical debridement and antimycobacterial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"     1",
"    </a>",
"    ]. We also suggest aggressive surgical intervention for osteomyelitis due to other NTM species when there is extensive local involvement, when an abscess is present, or when antimycobacterial therapy alone is poorly tolerated or does not result in clinical improvement. We recommend early surgical intervention for NTM species that are difficult to treat medically, such as M. chelonae and M. abscessus. A combined medical and surgical approach is also recommended for patients with vertebral osteomyelitis in order to minimize the risk of neurologic sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/34\">",
"     34",
"    </a>",
"    ]. Surgery should also be performed when the closed spaces of the hand are involved; this is most likely to occur with M. marinum infection since infection with this species is usually acquired through handling the contents of fish tanks.",
"   </p>",
"   <p>",
"    Several papers have described the use of bone cement [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/35-39\">",
"     35-39",
"    </a>",
"    ], beads [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/40-42\">",
"     40-42",
"    </a>",
"    ], and spacers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/43,44\">",
"     43,44",
"    </a>",
"    ] impregnated with antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/45\">",
"     45",
"    </a>",
"    ] in the setting of osteomyelitis. However, few reports have described these procedures in patients with mycobacterial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/39,46-48\">",
"     39,46-48",
"    </a>",
"    ]. Systemic toxicity has been reported with antibiotic-laden bone cement [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. As an example, two cases of acute kidney injury were associated with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    -laden cement incorporated in total hip arthroplasties, and both patients had elevated serum tobramycin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/50\">",
"     50",
"    </a>",
"    ]. When aminoglycoside-laden cement is used, serum aminoglycoside concentrations should be monitored. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/34/24104?source=see_link&amp;anchor=H22#H22\">",
"     \"Aminoglycosides\", section on 'Monitoring serum aminoglycoside concentrations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/34/24104?source=see_link&amp;anchor=H27#H27\">",
"     \"Aminoglycosides\", section on 'Toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1979020388\">",
"    <span class=\"h1\">",
"     MANAGING POOR TREATMENT RESPONSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients will respond to therapy with improvement in symptoms and serum inflammatory markers (C-reactive protein, erythrocyte sedimentation rate) within the first month of therapy. Improvement in imaging studies will take longer, often months after treatment initiation. If the patient does not respond to antimycobacterial therapy, we suggest surgical debridement, repeating cultures and performing (or repeating) in vitro susceptibility testing, and additional antimycobacterial therapy, such as the addition of a parenteral agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1979019417\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the rarity of nontuberculous mycobacteria (NTM) osteomyelitis and the sparsity of studies, the outcomes of NTM osteomyelitis have not been clearly defined. Outcomes depend on several factors, including the immune status of the host, the extent and location of the infection, and the causative species. As an example of the differences in outcome based upon the causative species, in an observational study that included 76 patients with nonpulmonary infections due to M. fortuitum, 68 patients (90 percent) were successfully treated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/39/13946/abstract/7\">",
"     7",
"    </a>",
"    ]. Most patients had skin and soft tissue infections, but 15 had osteomyelitis. The same study included 47 patients with nonpulmonary infections due to M. chelonae or M. abscessus, of whom 34 patients (72 percent) were successfully treated. Only seven of these patients had osteomyelitis. The major cause of treatment failure was the absence of an oral drug with activity against M. abscessus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542359714\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteomyelitis caused by nontuberculous mycobacteria (NTM) requires combination antimycobacterial therapy often in conjunction with surgery. (See",
"      <a class=\"local\" href=\"#H1649190421\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest combination antimycobacterial therapy for patients with osteomyelitis due to NTM (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The choice of the antimycobacterial regimen should be chosen based upon the usual regimens given for the specific NTM species isolated and, for certain species, on the results of in vitro susceptibility testing. Concomitant immunosuppression should be minimized whenever possible. Specific regimens for each NTM species are discussed above. (See",
"      <a class=\"local\" href=\"#H758105564\">",
"       'Antimycobacterial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with localized osteomyelitis due to M. avium complex, we suggest a combination of excisional surgery or surgical debridement and antimycobacterial therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We also suggest surgical debridement (in addition to antimycobacterial therapy) for patients with osteomyelitis due to other NTM species when there is extensive local involvement, an abscess, vertebral osteomyelitis, involvement of the closed spaces of the hand, or when antimycobacterial therapy alone is poorly tolerated or does not result in clinical improvement (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Surgery is indicated for NTM species that are difficult to treat medically, such as M. chelonae and M. abscessus. (See",
"      <a class=\"local\" href=\"#H115152665\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In vitro susceptibility testing is recommended for the majority of NTM species isolated from the lesions of patients with osteomyelitis, but specific recommendations differ for each species. (See",
"      <a class=\"local\" href=\"#H1979020487\">",
"       'Susceptibility testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration of antimycobacterial therapy depends upon several factors, including the response to treatment, the causative species, and the immune status of the patient. Antimycobacterial therapy is typically continued for a minimum of six months and is sometimes given for 12 months or longer. (See",
"      <a class=\"local\" href=\"#H14965826\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the patient does not respond to antimycobacterial therapy, we suggest surgical debridement, repeating cultures and performing (or repeating) susceptibility testing, and additional antimycobacterial therapy, such as the addition of a parenteral agent. (See",
"      <a class=\"local\" href=\"#H1979020388\">",
"       'Managing poor treatment responses'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/1\">",
"      Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/2\">",
"      Stone MS, Wallace RJ Jr, Swenson JM, et al. Agar disk elution method for susceptibility testing of Mycobacterium marinum and Mycobacterium fortuitum complex to sulfonamides and antibiotics. Antimicrob Agents Chemother 1983; 24:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/3\">",
"      Swenson JM, Wallace RJ Jr, Silcox VA, Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985; 28:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/4\">",
"      Brown BA, Wallace RJ Jr, Onyi GO, et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992; 36:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/5\">",
"      Wallace RJ Jr, Brown BA, Onyi GO. Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1991; 35:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/6\">",
"      Nash KA, Zhang Y, Brown-Elliott BA, Wallace RJ Jr. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J Antimicrob Chemother 2005; 55:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/7\">",
"      Wallace RJ Jr, Swenson JM, Silcox VA, Bullen MG. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis 1985; 152:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/8\">",
"      Wallace RJ Jr, Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 1992; 166:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/9\">",
"      Wallace RJ Jr, Brown-Elliott BA, Ward SC, et al. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001; 45:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/10\">",
"      Ad&eacute;kambi T, Reynaud-Gaubert M, Greub G, et al. Amoebal coculture of \"Mycobacterium massiliense\" sp. nov. from the sputum of a patient with hemoptoic pneumonia. J Clin Microbiol 2004; 42:5493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/11\">",
"      Ad&eacute;kambi T, Berger P, Raoult D, Drancourt M. rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int J Syst Evol Microbiol 2006; 56:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/12\">",
"      Leao SC, Tortoli E, Euz&eacute;by JP, Garcia MJ. Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. Int J Syst Evol Microbiol 2011; 61:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/13\">",
"      Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/14\">",
"      Choi GE, Shin SJ, Won CJ, et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012; 186:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/15\">",
"      Jarand J, Levin A, Zhang L, et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011; 52:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/16\">",
"      Jeon K, Kwon OJ, Lee NY, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009; 180:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/17\">",
"      Wallace RJ Jr, Nash DR, Tsukamura M, et al. Human disease due to Mycobacterium smegmatis. J Infect Dis 1988; 158:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/18\">",
"      Wallace RJ Jr, Bedsole G, Sumter G, et al. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob Agents Chemother 1990; 34:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/19\">",
"      Bernard L, Vincent V, Lortholary O, et al. Mycobacterium kansasii septic arthritis: French retrospective study of 5 years and review. Clin Infect Dis 1999; 29:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/20\">",
"      Yano T, Okuda S, Kato K, et al. Mycobacterium kansasii osteomyelitis in a patient with AIDS on highly active antiretroviral therapy. Intern Med 2004; 43:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/21\">",
"      Tsai CW, Wang JT, Tsai CC, Yeh KH. Disseminated Mycobacterium kansasii infection in an HIV-negative patient presenting with mimicking multiple bone metastases. Diagn Microbiol Infect Dis 2006; 54:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/22\">",
"      Williams B, Neth O, Shingadia D, et al. Mycobacterium kansasii causing septic arthritis and osteomyelitis in a child. Pediatr Infect Dis J 2010; 29:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/23\">",
"      Pezzia W, Raleigh JW, Bailey MC, et al. Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev Infect Dis 1981; 3:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/24\">",
"      Ahn CH, Lowell JR, Ahn SS, et al. Chemotherapy for pulmonary disease due to Mycobacterium kansasii: efficacies of some individual drugs. Rev Infect Dis 1981; 3:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/25\">",
"      Ahn CH, Lowell JR, Ahn SS, et al. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am Rev Respir Dis 1983; 128:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/26\">",
"      Banks J, Hunter AM, Campbell IA, et al. Pulmonary infection with Mycobacterium kansasii in Wales, 1970-9: review of treatment and response. Thorax 1983; 38:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/27\">",
"      Elsayed S, Read R. Mycobacterium haemophilum osteomyelitis: case report and review of the literature. BMC Infect Dis 2006; 6:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/28\">",
"      Shah MK, Sebti A, Kiehn TE, et al. Mycobacterium haemophilum in immunocompromised patients. Clin Infect Dis 2001; 33:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/29\">",
"      Bernard EM, Edwards FF, Kiehn TE, et al. Activities of antimicrobial agents against clinical isolates of Mycobacterium haemophilum. Antimicrob Agents Chemother 1993; 37:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/30\">",
"      McBride ME, Rudolph AH, Tschen JA, et al. Diagnostic and therapeutic considerations for cutaneous Mycobacterium haemophilum infections. Arch Dermatol 1991; 127:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/31\">",
"      Aubry A, Chosidow O, Caumes E, et al. Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Arch Intern Med 2002; 162:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/32\">",
"      Etuaful S, Carbonnelle B, Grosset J, et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 2005; 49:3182.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Buruli ulcer (Mycobacterium ulcerans infection). file://www.who.int/buruli/en/ (Accessed on June 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/34\">",
"      Petitjean G, Fluckiger U, Sch&auml;ren S, Laifer G. Vertebral osteomyelitis caused by non-tuberculous mycobacteria. Clin Microbiol Infect 2004; 10:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/35\">",
"      Marr MA, Algozzine GJ. Use of bone cement containing tobramycin sulfate. Clin Pharm 1983; 2:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/36\">",
"      Klekamp J, Dawson JM, Haas DW, et al. The use of vancomycin and tobramycin in acrylic bone cement: biomechanical effects and elution kinetics for use in joint arthroplasty. J Arthroplasty 1999; 14:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/37\">",
"      Hanssen AD, Spangehl MJ. Practical applications of antibiotic-loaded bone cement for treatment of infected joint replacements. Clin Orthop Relat Res 2004; :79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/38\">",
"      Gonz&aacute;lez Della Valle A, Bostrom M, Brause B, et al. Effective bactericidal activity of tobramycin and vancomycin eluted from acrylic bone cement. Acta Orthop Scand 2001; 72:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/39\">",
"      Scott CP, Higham PA, Dumbleton JH. Effectiveness of bone cement containing tobramycin. An in vitro susceptibility study of 99 organisms found in infected joint arthroplasty. J Bone Joint Surg Br 1999; 81:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/40\">",
"      Nelson CL, Griffin FM, Harrison BH, Cooper RE. In vitro elution characteristics of commercially and noncommercially prepared antibiotic PMMA beads. Clin Orthop Relat Res 1992; :303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/41\">",
"      Adams K, Couch L, Cierny G, et al. In vitro and in vivo evaluation of antibiotic diffusion from antibiotic-impregnated polymethylmethacrylate beads. Clin Orthop Relat Res 1992; :244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/42\">",
"      Seeley SK, Seeley JV, Telehowski P, et al. Volume and surface area study of tobramycin-polymethylmethacrylate beads. Clin Orthop Relat Res 2004; :298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/43\">",
"      Evans RP. Successful treatment of total hip and knee infection with articulating antibiotic components: a modified treatment method. Clin Orthop Relat Res 2004; :37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/44\">",
"      Greene N, Holtom PD, Warren CA, et al. In vitro elution of tobramycin and vancomycin polymethylmethacrylate beads and spacers from Simplex and Palacos. Am J Orthop (Belle Mead NJ) 1998; 27:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/45\">",
"      Kuechle DK, Landon GC, Musher DM, Noble PC. Elution of vancomycin, daptomycin, and amikacin from acrylic bone cement. Clin Orthop Relat Res 1991; :302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/46\">",
"      Masri BA, Duncan CP, Jewesson P, et al. Streptomycin-loaded bone cement in the treatment of tuberculous osteomyelitis: an adjunct to conventional therapy. Can J Surg 1995; 38:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/47\">",
"      Kerens B, Gans EH, Pilot P, et al. [Atypical tuberculous osteomyelitis of the humeral shaft caused by Mycobacterium avium]. Ned Tijdschr Geneeskd 2006; 150:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/48\">",
"      Pring M, Eckhoff DG. Mycobacterium chelonae infection following a total knee arthroplasty. J Arthroplasty 1996; 11:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/49\">",
"      Curtis JM, Sternhagen V, Batts D. Acute renal failure after placement of tobramycin-impregnated bone cement in an infected total knee arthroplasty. Pharmacotherapy 2005; 25:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/39/13946/abstract/50\">",
"      Patrick BN, Rivey MP, Allington DR. Acute renal failure associated with vancomycin- and tobramycin-laden cement in total hip arthroplasty. Ann Pharmacother 2006; 40:2037.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13995 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-88.81.100.162-4217E6CC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_39_13946=[""].join("\n");
var outline_f13_39_13946=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H542359714\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542359567\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1649190421\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1979020487\">",
"      SUSCEPTIBILITY TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H758105564\">",
"      ANTIMYCOBACTERIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H542359581\">",
"      Rapidly growing mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H542359588\">",
"      - M. fortuitum complex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H542359595\">",
"      - M. chelonae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H542359602\">",
"      - M. abscessus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H542359609\">",
"      - M. smegmatis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H542359616\">",
"      Slowly growing mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H542359623\">",
"      - M. avium complex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H542359630\">",
"      - M. kansasii",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H542359637\">",
"      - M. haemophilum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H542359644\">",
"      - M. marinum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H542359651\">",
"      - M. ulcerans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H51756785\">",
"      - Other species",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14965826\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14974796\">",
"      Monitoring during therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14973260\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14973535\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115152665\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1979020388\">",
"      MANAGING POOR TREATMENT RESPONSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1979019417\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542359714\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/13995\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/13995|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/0/3085\" title=\"table 1\">",
"      Mycobacteria classification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/34/24104?source=related_link\">",
"      Aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=related_link\">",
"      Azithromycin, clarithromycin, and telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39033?source=related_link\">",
"      Buruli ulcer (Mycobacterium ulcerans infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24089?source=related_link\">",
"      Epidemiology of nontuberculous mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/30/39401?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of osteomyelitis due to nontuberculous mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30757?source=related_link\">",
"      Ethambutol: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=related_link\">",
"      Hematogenous osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41943?source=related_link\">",
"      Isoniazid hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19142?source=related_link\">",
"      Isoniazid: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=related_link\">",
"      Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=related_link\">",
"      Microbiology of nontuberculous mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38777?source=related_link\">",
"      Mycobacterium avium complex (MAC) infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=related_link\">",
"      Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15512?source=related_link\">",
"      Overview of nontuberculous mycobacteria (excluding MAC) in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=related_link\">",
"      Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28298?source=related_link\">",
"      Pharmacology of antimicrobial agents for treatment of methicillin-resistant Staphylococcus aureus and vancomycin resistant enterococcus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5530?source=related_link\">",
"      Rapidly growing mycobacterial infections in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=related_link\">",
"      Rifampin and other rifamycins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=related_link\">",
"      Skeletal tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31687?source=related_link\">",
"      Soft tissue infections following water exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10646?source=related_link\">",
"      Treatment and prevention of osteomyelitis following trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24730?source=related_link\">",
"      Treatment of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2441?source=related_link\">",
"      Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22985?source=related_link\">",
"      Vertebral osteomyelitis and discitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_39_13947="SGA perinatal mortality";
var content_f13_39_13947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Perinatal mortality in SGA infants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Weight",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Rate",
"per 1000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        37 to 38 weeks",
"       </td>",
"       <td class=\"subtitle2\">",
"        39 to 40 weeks",
"       </td>",
"       <td class=\"subtitle2\">",
"        41 to 42 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AGA* 2750 to 3999 g",
"       </td>",
"       <td>",
"        6.7",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"       <td>",
"        4.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SGA&bull;",
"1500 to 2500 g",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        140",
"       </td>",
"       <td>",
"        145.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SGA &lt;1500 g",
"       </td>",
"       <td>",
"        547",
"       </td>",
"       <td>",
"        603",
"       </td>",
"       <td>",
"        545",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Appropriate for gestational age.",
"     <br>",
"      &bull; Small for gestational age.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Williams RL, Creasy RK, Cunningham GC, et al. Obstet Gynecol 1982; 59:624.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_39_13947=[""].join("\n");
var outline_f13_39_13947=null;
var title_f13_39_13948="Physical examination in HTN";
var content_f13_39_13948=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F69470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F69470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Important aspects of the physical examination in the hypertensive patient",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Accurate measurement of blood pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        General appearance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distribution of body fat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscle strength",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alertness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Fundoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Papilledema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cotton-wool spots",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neck",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palpation and auscultation of carotids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Heart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Size",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhythm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sounds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Lungs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhonchi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rales",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Abdomen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal masses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bruits over aorta or renal arteries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Femoral pulses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Extremities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral pulses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurologic assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Visual disturbance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Focal weakness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Confusion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_39_13948=[""].join("\n");
var outline_f13_39_13948=null;
var title_f13_39_13949="Actions of immunosuppressives";
var content_f13_39_13949=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F78362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F78362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mechanisms of action of immunosuppressive drugs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\" rowspan=\"6\">",
"        Glucocorticoids",
"       </td>",
"       <td>",
"        Inhibits phospholipase A2, cyclooxygenase 2, and nitric oxide",
"synthetase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibits production of pro-inflammatory prostaglandins,",
"leukotrienes, and thromboxanes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibits production of IL-1, IL-2, and tumor necrosis",
"factor-alpha",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibits neutrophil adhesion to endothelium and chemotaxis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibits monocyte/macrophage activation, chemotaxis, and",
"ability to recognize antigen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibits T lymphocyte proliferative response to antigen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" rowspan=\"8\">",
"        Methotrexate",
"       </td>",
"       <td>",
"        Stimulates adenosine release from",
"fibroblasts and endothelial",
"cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduces neutrophil adhesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antiproliferative effect on synovial fibroblasts and",
"endothelial cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibits leukotriene B4 synthesis by neutrophils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibits local IL-1 production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduces levels of IL-6 and IL-8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suppresses cell-mediated immunity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibits synovial collagenase gene expression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" rowspan=\"4\">",
"        Hydroxychloroquine",
"       </td>",
"       <td>",
"        Interferes with normal antigen",
"processing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibits lysosomal enzymes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibits IL-1 release",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibits polymorphonuclear and lymphocyte responses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" rowspan=\"3\">",
"        Sulfasalazine",
"       </td>",
"       <td>",
"        Inhibits polymorphonuclear cell",
"migration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduces lymphocyte responses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibits angiogenesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" rowspan=\"4\">",
"        Azathioprine",
"       </td>",
"       <td>",
"        Purine analogue; inhibts purine",
"metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibits B- and T-cell lymphocyte functions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibits B-cell proliferation and antibody synthesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibits natural killer cell activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" rowspan=\"4\">",
"        Cyclophosphamide and",
"chlorambucil",
"       </td>",
"       <td>",
"        Alkylating agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crosslinks DNA leading to cell death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Produces B- and T-cell lymphocytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibits immunoglobulin synthesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" rowspan=\"4\">",
"        Cyclosporine and tacrolimus",
"(FK506)",
"       </td>",
"       <td>",
"        Blocks transcription of IL-2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suppresses T-cell activation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preferential effect on CD4+ T-lymphocyte",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blocks synthesis and release of IL-1 from monocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Etanercept",
"       </td>",
"       <td>",
"        Neutralizes soluble",
"TNF-alpha, preventing it from",
"binding to cell bound",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" rowspan=\"3\">",
"        Infliximab and adalimumab",
"       </td>",
"       <td>",
"        Combine with tumor necrosis factor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Down-regulate endothelial cell adhesion molecules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreases leukocyte migration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Leflunomide",
"       </td>",
"       <td>",
"        Inhibits dihydro-orate dehydrogenase",
"which leads to depletion",
"of intracellular pyrimidine and reduces RNA synthesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Anakinra",
"       </td>",
"       <td>",
"        IL-1 receptor antagonist",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_39_13949=[""].join("\n");
var outline_f13_39_13949=null;
var title_f13_39_13950="Drugs immune hemolytic anemia";
var content_f13_39_13950=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F75322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F75322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs associated with immune hemolytic anemia and/or a positive DAT (Coombs test)*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td>",
"          Aceclofenac",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Acetaminophen",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Aminopyrine/pyramidon",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Amoxicillin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Amphotericin B",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ampicillin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Antazoline",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Butizide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Carbenicillin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Carbimazole",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Carboplatin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Carbromal",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Catergen/cyanidanol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cefamandole",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cefazolin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cefixime",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cefotaxime",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cefotetan",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cefoxitin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ceftazidime",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ceftizoxime",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ceftriaxone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cephalexin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cephaloridine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cephalothin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chlordiazepoxide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chlorinated hydrocarbons",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chlorpromazine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chlorpropamide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cianidanol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cisplatin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cladribine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Clavulanate potassium",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diclofenac",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td>",
"          Diethylstilbestrol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diphenylhydantoin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Dipyrone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Erythromycin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Etodolac",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fenoprofen",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fludarabine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fluorescein",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fluoroquinolones (eg, temafloxacin)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fluorouracil",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Glafenine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hydrazlazine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hydrochlorothiazide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          9-hydroxy-methyl- ellipticinium",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ibuprofen",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Indene derivatives (eg, sulindac)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Insulin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Interferon",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Interleukin-2",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Isoniazid",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Latamoxef",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Levodopa",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Mefenamic acid",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Mefloquine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Melphalan",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          6-mercaptopurine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Methicillin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Methotrexate",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Methyldopa",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Metrizoate-based radiographic contrast media",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Nafcillin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Nomifensine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Norfloxacin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Oxaliplatin",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td>",
"          p-aminosalicylic acid",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Penicillin G",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Phenacetin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Piperacillin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Probenicid",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Procainamide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Propyphenazone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Quinidine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Quinine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ranitidine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Rifampicin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sodium pentothal/thiopental",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Stibophen",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Streptokinase",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Streptomycin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sulbactam sodium",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sulindac",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sulfonamides",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sulfasalazide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sulfonylurea derivatives",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          (eg, chlorpropamide and tolbutamide)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Suprofen",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tazobactam sodium",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Teicoplanin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Temafloxacin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Teniposide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tetracycline",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ticarcillin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tolbutamide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tolmetin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Triamterene",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Trimetallic anhydride",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Zomepirac",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <br>",
"      * Only drugs with serologic evidence for the presence of antibodies (indirect and/or direct) have been included in this table.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Arndt, P, Garraty, G. The changing spectrum of drug-induced immune hemolytic anemia. Seminars in Hematology 2005; 42:138. Copyright &copy; 2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_39_13950=[""].join("\n");
var outline_f13_39_13950=null;
var title_f13_39_13951="B lines";
var content_f13_39_13951=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    B lines on thoracic ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pleural ultrasound image depicting B lines (\"comet tail artifact\"), which are seen in acute pulmonary edema and acute respiratory distress syndrome. The presence of B lines would provide an alternate explanation for increased density seen on the chest radiograph, other than pleural fluid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_39_13951=[""].join("\n");
var outline_f13_39_13951=null;
